» Articles » PMID: 35440003

Integrative Analysis of Therapy Resistance and Transcriptomic Profiling Data in Glioblastoma Cells Identifies Sensitization Vulnerabilities for Combined Modality Radiochemotherapy

Overview
Journal Radiat Oncol
Publisher Biomed Central
Specialties Oncology
Radiology
Date 2022 Apr 20
PMID 35440003
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Inherent resistance to radio/chemotherapy is one of the major reasons for early recurrence, treatment failure, and dismal prognosis of glioblastoma. Thus, the identification of resistance driving regulators as prognostic and/or predictive markers as well as potential vulnerabilities for combined modality treatment approaches is of pivotal importance.

Methods: We performed an integrative analysis of treatment resistance and DNA damage response regulator expression in a panel of human glioblastoma cell lines. mRNA expression levels of 38 DNA damage response regulators were analyzed by qRT-PCR. Inherent resistance to radiotherapy (single-shot and fractionated mode) and/or temozolomide treatment was assessed by clonogenic survival assays. Resistance scores were extracted by dimensionality reduction and subjected to correlation analyses with the mRNA expression data. Top-hit candidates with positive correlation coefficients were validated by pharmacological inhibition in clonogenic survival assays and DNA repair analyses via residual γH2AX/53BP1-foci staining.

Results: Inherent resistance to single-shot and similarly also to fractionated radiotherapy showed strong positive correlations with mRNA expression levels of known vulnerabilities of GBM, including PARP1, NBN, and BLM, as well as ATR and LIG4-two so far underestimated targets. Inhibition of ATR by AZD-6738 resulted in robust and dose-dependent radiosensitization of glioblastoma cells, whereas LIG4 inhibition by L189 had no noticeable impact. Resistance against temozolomide showed strong positive correlation with mRNA expression levels of MGMT as to be expected. Interestingly, it also correlated with mRNA expression levels of ATM, suggesting a potential role of ATM in the context of temozolomide resistance in glioblastoma cells. ATM inhibition exhibited slight sensitization effects towards temozolomide treatment in MGMT low expressing glioblastoma cells, thus encouraging further characterization.

Conclusions: Here, we describe a systematic approach integrating clonogenic survival data with mRNA expression data of DNA damage response regulators in human glioblastoma cell lines to identify markers of inherent therapy resistance and potential vulnerabilities for targeted sensitization. Our results provide proof-of-concept for the feasibility of this approach, including its limitations. We consider this strategy to be adaptable to other cancer entities as well as other molecular data qualities, and its upscaling potential in terms of model systems and observational data levels deserves further investigation.

Citing Articles

Identification and validation of a prognostic risk model based on radiosensitivity-related genes in nasopharyngeal carcinoma.

Li Y, Hong X, Xu W, Guo J, Su Y, Li H Transl Oncol. 2024; 52():102243.

PMID: 39675252 PMC: 11713735. DOI: 10.1016/j.tranon.2024.102243.


Chemical Activation and Mechanical Sensitization of Piezo1 Enhance TRAIL-Mediated Apoptosis in Glioblastoma Cells.

Knoblauch S, Desai S, Dombroski J, Sarna N, Hope J, King M ACS Omega. 2023; 8(19):16975-16986.

PMID: 37214705 PMC: 10193566. DOI: 10.1021/acsomega.3c00705.


Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.

Schnoller L, Piehlmaier D, Weber P, Brix N, Fleischmann D, Nieto A Radiat Oncol. 2023; 18(1):51.

PMID: 36906590 PMC: 10007763. DOI: 10.1186/s13014-023-02241-4.


Proton pump inhibitors display anti-tumour potential in glioma.

Li B, Liu Y, Sun S Cell Prolif. 2022; 56(7):e13321.

PMID: 35961680 PMC: 10334276. DOI: 10.1111/cpr.13321.


Polyoxometalate Nanoparticles as a Potential Glioblastoma Therapeutic via Lipid-Mediated Cell Death.

Petronek M, Allen B, Luthe G, Stolwijk J Int J Mol Sci. 2022; 23(15).

PMID: 35897839 PMC: 9332768. DOI: 10.3390/ijms23158263.

References
1.
Dote H, Burgan W, Camphausen K, Tofilon P . Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res. 2006; 66(18):9211-20. DOI: 10.1158/0008-5472.CAN-06-2181. View

2.
Lamarche B, Orazio N, Weitzman M . The MRN complex in double-strand break repair and telomere maintenance. FEBS Lett. 2010; 584(17):3682-95. PMC: 2946096. DOI: 10.1016/j.febslet.2010.07.029. View

3.
Barnieh F, Loadman P, Falconer R . Progress towards a clinically-successful ATR inhibitor for cancer therapy. Curr Res Pharmacol Drug Discov. 2021; 2:100017. PMC: 8663972. DOI: 10.1016/j.crphar.2021.100017. View

4.
Unkel S, Belka C, Lauber K . On the analysis of clonogenic survival data: Statistical alternatives to the linear-quadratic model. Radiat Oncol. 2016; 11:11. PMC: 4730743. DOI: 10.1186/s13014-016-0584-z. View

5.
Petroni M, Sardina F, Infante P, Bartolazzi A, Locatelli E, Fabretti F . MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Cell Death Dis. 2018; 9(9):895. PMC: 6117286. DOI: 10.1038/s41419-018-0924-z. View